



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 18TH NOVEMBER 2020

PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

Dr Ramtoola was welcomed to the meeting as the new chairperson for ELMMB.

2020/117: APOLOGIES:

Dr T McKenzie (TM)	GP East Lancs
--------------------	---------------

2020/118: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2020/119: MINUTES OF OCTOBER Teams MEETING:

Accepted as a correct record.

2020/120: MATTERS ARISING:

2019/131: Treatment of Vitamin B12 Deficiency Draft – A pathway is currently being developed with Jane Oakey from Path Lab who is exploring options re. active B12 testing in path lab. Deferred due to pressures from Covid-19 related issues. To be brought to ELMMB in early 2021.

2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta® - JV arranging meeting to consider their place on primary care guidelines. Deferred due to pressures from Covid-19 related issues. To be brought to ELMMB in early 2021.

2020/092: Drug Safety Update – Denosumab – Deferred due to pressures from Covid-19 related issues. To be brought to ELMMB in early 2021 and include endocrinologists.

2020/105: Formulary Updates – Contour Plus/Next – resources on website have been updated and consolidated into one location.

2020/107 Adrenaline Auto Injector Position Statement & Patient Information Leaflet – not progressed due to pressure from Covid-19 related issues. To be brought to ELMMB in early 2021.

Deferred from October

2020/108: NON-CANCER PAIN GUIDELINE – OPIOID TAPERING & WITHDRAWAL

The process of aligning opioid tapering & withdrawal guidance from various guidance documents on website is underway. It will be brought back to ELMMB when work is completed.

Resolved: Opioid tapering & withdrawal guidance to be brought to ELMMB when completed.

New Items

2020/121: NEW PRODUCT REQUEST – BISMUTH SUBSALICYLATE (PEPTO-BISMOL®)

Requested by gastroenterology consultants, for the treatment of Helicobacter Pylori. It is included in NICE guidance in first and second line regimen options when patients are allergic to penicillin and have had previous exposure to other first/second line antibiotics. It is also requested as part of quadruple therapy when patients have not responded to first & second line options. ELMMB approved bismuth subsalicylate for addition to formulary for use in line with NICE guidance as a green traffic light and as part of quadruple therapy as an amber traffic light.

Resolved: Bismuth Subsalicylate included on formulary for use in Helicobacter Pylori in accordance with NICE and on the recommendation of gastroenterology as part of quadruple therapy **Traffic Light: GREEN (in line with NICE)**
Traffic Light: AMBER (as part of quadruple therapy)

2020/122: NEW PRODUCT REQUEST – SALICYLIC ACID OINTMENT BP

Requested by dermatology consultants for the treatment of hyperkeratotic and scaling conditions. It would be used in place of Lan Vas Sal ointment which is unlicensed, obtained as a special and very expensive. Use of salicylic acid ointment BP as a keratolytic is licensed and is supported in the BAD list. GP's would want the initial recommendation to come from a specialist. ELMMB approved salicylic acid ointment BP for addition to the formulary with and amber traffic light.

Resolved: Salicylic acid ointment BP added to formulary. Traffic Light: AMBER

2020/123: UNLICENSED PRODUCT REQUEST – NYSTATIN PESSARY

Requested by dermatology consultants for the treatment of recurrent vulvovaginal candidiasis and azole resistance. It is included in the national guideline from BASHH for this indication and would be used in line with this guidance on dermatology advice. Patients would be counselled on its dose and use as it is an unlicensed preparation. ELMMB approved unlicensed nystatin pessaries for addition to formulary with a red traffic light.

Resolved: Nystatin pessaries added to formulary.

Traffic Light: RED

2020/124: LSCMMG CONSULTATIONS (FOR DECEMBER LSCMMG)

Esketamine for major depressive disorder New Medicines assessment –

ELMMB supports the recommendation for a black traffic light.

Ketamine injection for chronic non-cancer pain New Medicines assessment –

consultation withdrawn by LSCMMG for inclusion of oral ketamine.

Primary Care Headache Management Pathway – review of existing document with some minor updates to flow chart. Comments from ELMMB include:

Flow chart –

- Giant cell arteritis should be emergency referral (same day) rather than urgent referral.
- Prednisolone would not need to be started by GP if emergency referral
- Local referral would include acute medicine
- Referral to neurology within 2 weeks is not possible
- Headache service is not available

Giant cell arteritis box should state emergency referral not urgent referral and include acute medicine. Tocilizumab would not be started in primary care.

New onset headache in pregnancy should be referred to obstetrics

Migraine recommended therapy is limited – GP's would usually consider triptan injections if oral not effective.

Concern that this guideline is trying to do too much (acute and ongoing) and it has lost clarity.

Resolved: Comments to be sent to LSCMMG.

2020/125: LSCMMG Recommendations

Antipsychotic Shared Care Guideline –updated – cariprazine has been added.

Accepted as written for use in ELHE.

2020/126: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS

No meeting.

2020/127: FORMULARY UPDATES

Viscotears® Single dose eye gel – include in formulary for use by ophthalmology during procedures.

Traffic Light: RED

Diflucortone (Nerisone® /Nerisone Forte®) – discontinued. Remove from formulary.

Lubiprostone – discontinued. Remove from formulary. LSCMMG have been requested to review constipation guidance as it is currently included.

Resolved: Formulary to be updated as above.

2020/128: MANAGING BOWEL PREPARATIONS FOR PATIENTS UNDERGOING ENDOSCOPY

The trust has an issue with supply of bowel prep as there are increased referrals with patients having telephone appointments as the initial contact. Bowel prep is posted out to most patients and this requires repacking as part of dispensing. The trust would like to explore other options. We are aware one local trust requires patients to collect from hospital, and one posts out. Any suggestions for a way forward should be sent to Vince Goodey.

Managing bowel prep supplies is also being considered across the ICS.

Resolved: Any suggestion of a way forward to be sent to VG who will continue to find a suitable resolution.

2020/129: REMDESIVIR COMMISSIONING UPDATE

The CCGs asked for assurance that the trust was offering remdesivir to patients that meet the NHSE commissioning policy. The trust has this week agreed wording for the criteria to prescribe remdesivir and VG will bring this to next meeting.

Action: VG to update the next meeting with information on the prescribing of remdesivir in the trust.

2020/130: NICE RECOMMENDATIONS (from October)

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

Traffic Light: BLACK

Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer [TA653] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

2020/131: HIGHLY SPECISLISED TECHNOLOGIES GUIDANCE (from October)

Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Acknowledged

Additional Item: GOSERELIN FOR PROSTATE CANCER SHARED CARE

The shared care (which is due for review in Feb 2021) states that the first 3 months should be given in secondary care. Some GPs are declining to prescribe and this is posing issues for administration, as with telephone consultations patients are not attending hospital. (The bicalutamide to take with it is delivered by Rowlands). The trust would like first (and subsequent) doses to be prescribed in primary care on recommendation of a specialist. This was considered to be reasonable and agreed the shared care can be amended. CD to discuss with BwD clinicians and feed back to VG. The amendment to the shared care can be made if BwD also agrees

Action: CD to discuss with BwD clinicians. Shared care to be amended if agreed.

STANDING ITEMS

2020/132: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – September 2020

Minutes acknowledged

DATE OF NEXT MEETING – No meeting to be held in December

Next meeting is Wednesday 20th January 2021 12.30pm via ‘Microsoft Teams’

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 18TH NOVEMBER 2020

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed.	LR/JV	Mar 21
2020/015	New Product request – Relvar Ellipta® & Anoro Ellipta® - meeting to be arranged to consider place on primary care guidelines	JV	Mar 21
2020/092	Drug Safety Update – Denosumab Invite representatives from rheumatology, MSK & medicine for older people to next meeting	CW/AG/LR	Mar 21
2020/107	Adrenaline Auto Injector Position Statement & Patient Information Leaflet – discuss policies & procedures in schools with LCC	JV	Mar 21
2020/129	Remdesivir Commissioning Update - Update meeting on prescribing information for Remdesivir in the trust	VG	Jan 21
Additional item	Goserelin for prostate cancer Shared Care – discuss first dose in community with BwD clinicians Amend shared care if all in agreement	CD VG	Dec 21 Jan 21